Report of Foreign Issuer (6-k)
October 03 2017 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of October 2017
001-37353
(Commission File Number)
BIONDVAX
PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
14 Einstein St.
Ness Ziona
Israel 74036
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
____
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
CONTENTS
BiondVax Pharmaceuticals
Ltd. (the “
Company
”) hereby announces, in accordance with Sections 2.10.10.6 and 2.10.10.7 of the shelf prospectus
published in Israel on January 16, 2012, and in accordance to the shelf offering report published in Israel on October 27, 2013
(reference numbers: 2012-01-017205 and 2013-01-176046, respectively), that the tradable options (Series 5) issued by the Company
and traded only on the Tel Aviv Stock Exchange Ltd. (“TASE”), Ticker number BVXV.W5, TASE no. 1130400 and ISIN: IL0011304008
(“Series 5 options”), are exercisable until Sunday, October 29, 2017. In addition, the last trade day on TASE for Series
5 options is October 24, 2017. The exercise price of each Series 5 option is NIS 1.50 ($0.423 based on the exchange rate reported
by the Bank of Israel on October 2, 2017, which is 3.542=$1.00).
Series 5 options that
will not be exercised until October 29, 2017, shall expire and shall not grant any right whatsoever to its holders.
It is hereby clarified
that the Series 5 options are not listed for trade on The NASDAQ Capital Market.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: October 3, 2017
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
3
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024